miR-223-5p targeting ERG inhibits prostate cancer cell proliferation and migration

Wei, Yongbao1,2; Peng, Junming3; He, Shuyun4,5; Huang, Haijian1,6; Lin, Le1,2; Zhu, Qingguo1,2; Ye, Liefu1,2; Li, Tao1,2; Zhang, Xing7; Gao, Yun-Liang4; Zheng, Xiaochun1,8

2020

10.7150/jca.44441

Journal of Cancer   影响因子和分区

1837-9664

Ectopic expression of miR-223-5p, the lagging strand of miR-223 duplex, has been reported acting as anti-tumor miRNA in many cancers. How miR-223-5p influencing prostate cancer (PCa) remains obscure and worth of experimental investigation. In this study, the expressions of miR-223-5p and ERG in common PCa cell lines were detected and compared to RWPE-1, respectively. Then luciferase reporter assay was performed to verify whether miR-223-5p could specifically target and regulate ERG. Further discovery ERG's role in the PCa oncogenesis was also conducted by up or down regulating miR-223-3p expression. We found miR-223-5p was significantly down-regulated in DU145, while it was only up-regulated in LNCaP. Similarly, ERG expression remarkably decreased in both PC-3 and DU145 than that in RWPE-1, but significantly increasing in LNCaP. Luciferase assay demonstrated slightly decreased ERG expression after miR-223-5p-mimics but significantly increased ERG expression after miR-223-5p-inhibtor. Using gene interference, we further confirmed that both ERG mRNA and protein expressions were decreased in all PCa lines transfected ERG siRNA, but increasing in both DU145 and LNCaP cells with miR-223-5p antisense oligonucleotides. MTT assay, Transwell invasion and migration assay supported the function of ERG in PCa oncogenesis. We revealed tumor suppressive abilities of miR-223-5p in PCa by negatively targeting ERG gene. It could serve as a fundamental supplement and extension of our previous study about miR-223-3p in PCa, revealing the coordinative regulation between miR-223-5p and miR-223-3p in PCa cell biological behaviors. Exploration of miR-233-duplex orientated pathway networks may help us develop novel potential therapeutic options for PCa.

miR-223-5p prostate cancer ERG biological behavior

SCI

英语

其他

Joint Funds for the innovation of science and Technology, Fujian province[2017Y9064] ; Fujian Provincial Hospital, Fujian province, China[2019HSJJ29] ; Project of Science and Technology Plan of Xiangtan, China[SF-CP20173004]

Oncology

Oncology

WOS:000536447000017

IVYSPRING INT PUBL

Web of Science

1.Fujian Med Univ, Shengli Clin Med Coll, Fuzhou 350001, Peoples R China
2.Fujian Prov Hosp, Dept Urol, Fuzhou 350001, Peoples R China
3.Southern Univ Sci & Technol, Jinan Univ, Shenzhen Peoples Hosp, Dept Urol,Clin Med Coll 2,Affiliated Hosp 1, Shenzhen 518020, Peoples R China
4.Cent South Univ, Xiangya Hosp 2, Dept Urol, 139 Renmin Rd, Changsha 410011, Peoples R China
5.Peoples Hosp Xiangtan Country, Dept Urol, Xiangtan, Peoples R China
6.Fujian Prov Hosp, Dept Pathol, Fuzhou 350001, Peoples R China
7.Yangzhou Univ Tradit Chinese Med, Tradit Chinese Med Hosp Yangzhou, Dept Urol, Yangzhou 225002, Jiangsu, Peoples R China
8.Fujian Prov Hosp, Dept Anesthesiol, Fuzhou 350001, Peoples R China

Wei, Yongbao,Peng, Junming,He, Shuyun,et al. miR-223-5p targeting ERG inhibits prostate cancer cell proliferation and migration[J]. Journal of Cancer,2020,11(15):4453-4463.

Wei, Yongbao.,Peng, Junming.,He, Shuyun.,Huang, Haijian.,Lin, Le.,...&Zheng, Xiaochun.(2020).miR-223-5p targeting ERG inhibits prostate cancer cell proliferation and migration.Journal of Cancer,11(15),4453-4463.

Wei, Yongbao,et al."miR-223-5p targeting ERG inhibits prostate cancer cell proliferation and migration".Journal of Cancer 11.15(2020):4453-4463.